Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) have been assigned a consensus recommendation of “Buy” from the eight research firms that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $27.40.

A number of research firms have recently commented on DVAX. Cowen and Company reaffirmed an “outperform” rating and set a $30.00 target price on shares of Dynavax Technologies Corporation in a research note on Thursday, August 10th. Zacks Investment Research raised Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Monday, July 10th. BidaskClub cut Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. William Blair reaffirmed an “outperform” rating and set a $30.00 target price on shares of Dynavax Technologies Corporation in a research note on Wednesday, August 9th. Finally, J P Morgan Chase & Co raised Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and upped their target price for the company from $6.00 to $27.00 in a research note on Monday, July 31st.

Several hedge funds and other institutional investors have recently made changes to their positions in DVAX. Cubist Systematic Strategies LLC boosted its holdings in shares of Dynavax Technologies Corporation by 54.5% in the second quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 3,700 shares during the period. Patriot Financial Group Insurance Agency LLC boosted its holdings in shares of Dynavax Technologies Corporation by 16.5% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 1,700 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in shares of Dynavax Technologies Corporation in the first quarter valued at approximately $121,000. Bank of America Corp DE boosted its holdings in shares of Dynavax Technologies Corporation by 2.3% in the first quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 456 shares during the period. Finally, Legal & General Group Plc boosted its holdings in shares of Dynavax Technologies Corporation by 18.5% in the second quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 1,950 shares during the period. Hedge funds and other institutional investors own 60.20% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/dynavax-technologies-corporation-dvax-receives-27-40-consensus-target-price-from-analysts/1580558.html.

Dynavax Technologies Corporation (NASDAQ DVAX) traded down 1.082% during midday trading on Tuesday, reaching $20.575. The company’s stock had a trading volume of 335,551 shares. The firm’s market cap is $1.13 billion. The company’s 50-day moving average is $17.84 and its 200 day moving average is $9.78. Dynavax Technologies Corporation has a 12-month low of $3.20 and a 12-month high of $21.85.

Dynavax Technologies Corporation (NASDAQ:DVAX) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.09. The firm had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.15 million. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. During the same quarter in the prior year, the firm posted ($0.75) earnings per share. Equities analysts forecast that Dynavax Technologies Corporation will post ($1.60) earnings per share for the current year.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.